Curaleaf Holdings (CURLF) Change in Accured Expenses (2019 - 2024)
Curaleaf Holdings (CURLF) posted quarterly Change in Accured Expenses of -$178.1 million for Q4 2024, down 1047.84% year-on-year from $18.8 million in Q1 2024, and down 514.81% on a QoQ basis from $42.9 million in Q3 2024.
Curaleaf Holdings (CURLF) Change in Accured Expenses (2019 - 2024) Analysis & Trends
Curaleaf Holdings (CURLF) has reported Change in Accured Expenses for 6 consecutive years, with -$178.1 million the latest figure, recorded in Q4 2024.
- Quarterly Change in Accured Expenses fell 1047.84% year-over-year to -$178.1 million in Q4 2024, while the trailing twelve-month figure through Dec 2024 was -$157.1 million (down 481.58% YoY) and the FY2025 annual result came in at $147.9 million, up 24.91% from the prior year.
- Change in Accured Expenses retreated to -$178.1 million in Q4 2024 per CURLF's latest filing, from $42.9 million in the prior quarter.
- Over the last five years, Change in Accured Expenses for CURLF reached as high as $60.7 million in Q4 2021 and fell as low as -$178.1 million in Q4 2024.
- A 5-year average of -$1.3 million and a median of -$167500.0 in 2021 frame the typical range for Change in Accured Expenses.
- Annual changes were most pronounced in 2021 — Change in Accured Expenses soared 3430.68% — and 2022, when it tumbled 6757.89%.
- Year by year, Change in Accured Expenses stood at -$1.8 million in 2020, then surged by 3430.68% to $60.7 million in 2021, then dropped by 0.49% to $60.4 million in 2022, then plunged by 125.7% to -$15.5 million in 2023, then tumbled by 1047.84% to -$178.1 million in 2024.
- According to Business Quant data, Change in Accured Expenses over the past three periods registered -$178.1 million, $42.9 million, and -$15.5 million for Q4 2024, Q3 2024, and Q4 2023 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Accured Expenses (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 87.22 Bn | 85.35 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 39.60 Bn | 35.87 Bn | 1.97 Bn | -144.00 Mn |
| 3 | Zoetis | 31.46 Bn | 29.52 Bn | 1.62 Bn | -234.00 Mn |
| 4 | Takeda Pharmaceutical | 26.49 Bn | 22.44 Bn | 4.39 Bn | - |
| 5 | United Therapeutics | 23.03 Bn | 20.88 Bn | 648.10 Mn | -12.70 Mn |
| 6 | Universe Pharmaceuticals | 23.03 Bn | -10.56 Bn | - | - |
| 7 | Viatris | 20.90 Bn | 19.09 Bn | 1.16 Bn | - |
| 8 | Neurocrine Biosciences | 17.50 Bn | 16.19 Bn | 800.70 Mn | -14.30 Mn |
| 9 | Elanco Animal Health | 12.33 Bn | 11.91 Bn | 785.00 Mn | - |
| 10 | Curaleaf Holdings | 7.13 Bn | 7.13 Bn | 157.29 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2024 | -178.11 Mn |
| Dec 31, 2024 | -178.11 Mn |
| Sep 30, 2024 | 42.94 Mn |
| Sep 30, 2024 | 42.94 Mn |
| Dec 31, 2023 | -15.52 Mn |
| Dec 31, 2023 | -15.52 Mn |
| Sep 30, 2023 | -6.46 Mn |
| Sep 30, 2023 | -6.46 Mn |
| Dec 31, 2022 | 60.39 Mn |
| Dec 31, 2022 | 60.39 Mn |
| Sep 30, 2022 | 2.77 Mn |
| Sep 30, 2022 | 2.77 Mn |
| Jun 30, 2022 | -6.33 Mn |
| Jun 30, 2022 | -6.33 Mn |
| Mar 31, 2022 | -430,000.00 |
| Mar 31, 2022 | -430,000.00 |
| Dec 31, 2021 | 60.69 Mn |
| Dec 31, 2021 | 60.69 Mn |
| Sep 30, 2021 | 23.27 Mn |
| Sep 30, 2021 | 23.27 Mn |